Omnio AB, the biopharmaceutical company focused on revolutionizing the treatment of diabetic foot ulcers (DFUs), has secured $3.3M in new funding. The capital infusion will advance its work in developing recombinant plasminogen therapeutics.
The company's dedication to addressing DFUs, a debilitating condition affecting millions globally, underscores the critical need for innovative solutions in wound care. Omnio AB's approach with recombinant plasminogen aims to offer a novel pathway for healing these complex and often life-threatening wounds.


















